Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 973 (LINC00973)
- Target
- LINC00973
- Molecular classification
- Long non-coding RNA, Other
01
Overview
Long intergenic non-protein coding RNA 973 (LINC00973) is a human long non-coding RNA (lncRNA) implicated in the regulation of gene expression networks primarily through its action as a competing endogenous RNA (ceRNA), binding multiple microRNAs. LINC00973 has been found to promote cancer cell proliferation, reduce p21 levels, decrease drug-induced lethality in cancer cells, and is upregulated in various tumors such as non-small cell lung cancer and renal cell carcinoma. Elevated levels of LINC00973 are associated with poor prognosis in NSCLC, potentially through the modulation of cancer-related signaling pathways and key prognostic genes. Although there is evidence for its regulatory role in cancer progression, LINC00973 itself is not a classic therapeutic target such as a receptor, enzyme, or transporter, and there are currently no approved drugs that directly target it[1][2][3][4][5].
- Other names
- CTD-2021J15.2
02
Mechanism of action
Acts as a ceRNA (competing endogenous RNA), sponging specific microRNAs (miRNAs) and thereby modulating the expression of their target mRNAs[2][4]
03
Biological functions
Regulation of cell migrationResponse to oxygen levelsPositive regulation of cell cycle processEndothelial cell proliferationceRNA (competing endogenous RNA) activity (sponging miRNAs)Regulation of cancer-related signaling pathways (e.g., TGF-beta, PI3K-Akt, MAPK, Hippo, cellular senescence)
04
Disease associations
Cancer (especially non-small cell lung cancer, NSCLC; renal cell carcinoma; breast cancer; gastric cancer)Other
05
Safety considerations
None specifically reported. As an endogenous non-coding RNA, its manipulation may affect many pathways due to complex RNA networks, but this is a general property rather than a specific safety concern.
06
Interacting drugs
None known
07
Biomarkers
Increased expression has been associated with poor prognosis in NSCLC[2][4]Potentially regulates prognostic genes (such as BMP2, LOXL2, NFIX, PTX3, RTKN2) in NSCLC[4]
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 973 (LINC00973).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 973 (LINC00973).